These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 31242462)

  • 1. DIAGNOSIS OF ENDOCRINE DISEASE: Drug-induced endocrinopathies and diabetes: a combo-endocrinology overview.
    Diamanti-Kandarakis E; Duntas L; Kanakis GA; Kandaraki E; Karavitaki N; Kassi E; Livadas S; Mastorakos G; Migdalis I; Miras AD; Nader S; Papalou O; Poladian R; Popovic V; Rachoń D; Tigas S; Tsigos C; Tsilchorozidou T; Tzotzas T; Bargiota A; Pfeifer M
    Eur J Endocrinol; 2019 Aug; 181(2):R73-R105. PubMed ID: 31242462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update in Endocrine Pathology.
    Mete Ö
    Turk Patoloji Derg; 2015; 31 Suppl 1():1-3. PubMed ID: 26177313
    [No Abstract]   [Full Text] [Related]  

  • 3. Environmental estrogens and endocrine disruption: importance of comparative endocrinology.
    Foster WG
    Endocrinology; 2008 Sep; 149(9):4267-8. PubMed ID: 18511513
    [No Abstract]   [Full Text] [Related]  

  • 4. Reproducibility of endocrine disruption data.
    Ashby J; Elliott BM
    Regul Toxicol Pharmacol; 1997 Aug; 26(1 Pt 1):94-5. PubMed ID: 9339485
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug-induced endocrine and metabolic disorders.
    Ma RC; Kong AP; Chan N; Tong PC; Chan JC
    Drug Saf; 2007; 30(3):215-45. PubMed ID: 17343430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocrine disruptor risk characterization: an EPA perspective.
    Fenner-Crisp PA
    Regul Toxicol Pharmacol; 1997 Aug; 26(1 Pt 1):70-3. PubMed ID: 9339482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A toxicologically based weight-of-evidence methodology for the relative ranking of chemicals of endocrine disruption potential.
    Calabrese EJ; Baldwin LA; Kostecki PT; Potter TL
    Regul Toxicol Pharmacol; 1997 Aug; 26(1 Pt 1):36-40. PubMed ID: 9339477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine side effects induced by immune checkpoint inhibitors.
    Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vulnerability of the endocrine system to xenobiotic influence.
    Neubert D
    Regul Toxicol Pharmacol; 1997 Aug; 26(1 Pt 1):9-29. PubMed ID: 9339474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a Tier I screening battery for detecting endocrine-active compounds (EACs).
    Cook JC; Kaplan MA; Davis LG; O'Connor JC
    Regul Toxicol Pharmacol; 1997 Aug; 26(1 Pt 1):60-8. PubMed ID: 9339481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentialities of Gene Therapy in Pediatric Endocrinology.
    Frontino G; Stancampiano MR; Aiuti A
    Horm Res Paediatr; 2023; 96(6):646-657. PubMed ID: 34801996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrinopathy and Aging in Ferrets.
    Bakthavatchalu V; Muthupalani S; Marini RP; Fox JG
    Vet Pathol; 2016 Mar; 53(2):349-65. PubMed ID: 26936751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the risks of adverse endocrine-mediated effects: where to from here?
    Ashby J; Odum J; Tinwell H; Lefevre PA
    Regul Toxicol Pharmacol; 1997 Aug; 26(1 Pt 1):80-93. PubMed ID: 9339484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucocrinology.
    Kalra S; Priya G; Gupta Y
    J Pak Med Assoc; 2018 Jun; 68(6):963-965. PubMed ID: 30323371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrinology and metabolism.
    EMERSON K
    Am Pract Dig Treat; 1953 Apr; 4(4):44-52. PubMed ID: 13050909
    [No Abstract]   [Full Text] [Related]  

  • 16. The future endocrine patient. Reflections on the future of clinical endocrinology.
    Lamberts SW; Romijn JA; Wiersinga WM
    Eur J Endocrinol; 2003 Sep; 149(3):169-75. PubMed ID: 12943517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond screening: problems and prospects for risk characterization of endocrine disruptors.
    Rhomberg L
    Regul Toxicol Pharmacol; 1997 Aug; 26(1 Pt 1):74-9. PubMed ID: 9339483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of endocrine disruptors: approaches, issues, and uncertainties.
    Chen CW
    Folia Histochem Cytobiol; 2001; 39 Suppl 2():20-3. PubMed ID: 11820607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular genetic testing in endocrinology - a practical guide.
    Kirmani S
    Endocr Pract; 2012; 18(1):85-9. PubMed ID: 22336444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Frontiers in the Therapeutic Approach of Patients with Cardiovascular and Endocrine Diseases.
    Grande D; Terlizzese P; Gioia MI; Parisi G; Giagulli VA; Triggiani V; Iacoviello M
    Endocr Metab Immune Disord Drug Targets; 2019; 19(5):605-621. PubMed ID: 30621568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.